Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target
Seres Therapeutics Analyst Ratings
Oppenheimer Sticks to Their Hold Rating for Seres Therapeutics (MCRB)
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $10
CCORF analyst John Newman maintains $Seres Therapeutics(MCRB.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 38.6% and a
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference